AP1, AP4 invest in cancer drug firm via directed share issue

By 2017-12-06T13:52:00

Stockholm, Sweden

Swedish biotech firm Cantargia has a strong early-stage product, says AP1

You have now reached your article limit

Already a registered user or member? Sign in here

To continue reading, register free today for access

Register Now

Registration also includes access to

IPE Real Assets

Gated access promo

Five reasons to register today

  1. Access to IPE articles from our award-winning editorial team
  2. Unique IPE market data, rankings and tables
  3. In-depth interviews with pension fund leaders
  4. Extensive coverage of latest asset class trends
  5. Comprehensive archive of data, research and intelligence
SEE HOW IPE CAN HELP YOUR BUSINESS